Full Press Release Details
Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy.
SLDB
Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy
Key Takeaway: Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy